TotalEnergies begins production at BEGONIA and CLOV Phase 3 projects in Angola

Jacques Aschenbroich Lead Independent Director of TotalEnergies TotalEnergies SE
Jacques Aschenbroich Lead Independent Director of TotalEnergies - TotalEnergies SE
0Comments

TotalEnergies has announced the commencement of production from the BEGONIA and CLOV Phase 3 offshore projects in Angola, adding a combined total of 60,000 barrels per day. These projects are designed to leverage existing facilities with low costs and emissions.

The BEGONIA project marks the first inter-block development in Angola, facilitated by cooperation between TotalEnergies and its partners: Agencia Nacional de Petróleo, Gás e Biocombustíveis (ANPG), Sonangol E&P, SSI, ETU Energias, and Falcon Oil. Located 150 kilometers off the Angolan coast, it consists of five wells tied back to the PAZFLOR floating production storage and offloading unit (FPSO).

CLOV Phase 3 is another significant project for TotalEnergies in Block 17. In collaboration with ANPG and partners Equinor, ExxonMobil, Azule Energy, and Sonangol E&P, this development is located 140 kilometers from the coast. It features four wells tied back to the CLOV FPSO.

Nicolas Terraz of TotalEnergies stated that these developments align with their strategy to grow upstream production while reducing costs and emissions. Paulino Jerónimo from ANPG highlighted the importance of these projects for maintaining Angola’s oil production levels above one million barrels per day.

TotalEnergies has been active in Angola since 1953, employing around 1,500 people across various sectors including deep offshore operations which account for over 45% of Angola’s oil output.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.